Literature DB >> 8096290

Rapid decline of CD4+ cells after IFN alpha treatment in HIV-1 infection.

S Vento, G Di Perri, M Cruciani, T Garofano, E Concia, D Bassetti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8096290     DOI： 10.1016/0140-6736(93)91248-k

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  12 in total

Review 1.  The HCV and HIV coinfected patient: what have we learned about pathophysiology?

Authors:  Andrew H Talal; P Wilfredo Canchis; Ira Jacobson
Journal:  Curr Gastroenterol Rep       Date:  2002-02

2.  Treat early or wait and monitor? A qualitative analysis of provider hepatitis C virus treatment decision-making in the context of HIV coinfection.

Authors:  Glenn Wagner; Gery Ryan; Karen Chan Osilla; Laveeza Bhatti; Matthew Goetz; Mallory Witt
Journal:  AIDS Patient Care STDS       Date:  2009-09       Impact factor: 5.078

3.  T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy.

Authors:  A Arizcorreta; M Márquez; C Fernández-Gutiérrez; E Pérez Guzmán; F Brun; M Rodríguez-Iglesias; J A Girón-González
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

4.  Treatment of SIV-infected sooty mangabeys with a type-I IFN agonist results in decreased virus replication without inducing hyperimmune activation.

Authors:  Thomas H Vanderford; Chloe Slichter; Kenneth A Rogers; Benton O Lawson; Rend Obaede; James Else; Francois Villinger; Steven E Bosinger; Guido Silvestri
Journal:  Blood       Date:  2012-05-01       Impact factor: 22.113

5.  Hepatitis C and HIV-1 coinfection.

Authors:  A H Mohsen; P Easterbrook; C B Taylor; S Norris
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

6.  Characteristics of hepatitis C virus infection in HIV-infected people.

Authors:  C L Cooper; A D Badley; J B Angel
Journal:  Can J Infect Dis       Date:  2001-05

Review 7.  Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis.

Authors:  M Haria; P Benfield
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

8.  INCIDENCE OF TUBERCULOSIS AMONG HIV/HCV CO-INFECTED PATIENTS RECEIVING HEPATITIS C TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN IN GEORGIA.

Authors:  A Abutidze; N Bolokadze; N Chkhartishvili; L Sharvadze; T Tsertsvadze
Journal:  Georgian Med News       Date:  2016-03

9.  Altered thymic function during interferon therapy in HCV-infected patients.

Authors:  Stephanie Beq; Sandra Rozlan; Sandy Pelletier; Bernard Willems; Julie Bruneau; Jean-Daniel Lelievre; Yves Levy; Naglaa H Shoukry; Rémi Cheynier
Journal:  PLoS One       Date:  2012-04-16       Impact factor: 3.240

10.  The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UK.

Authors:  Jamie Inshaw; Clifford Leen; Martin Fisher; Richard Gilson; David Hawkins; Simon Collins; Julie Fox; Ken McLean; Sarah Fidler; Andrew Phillips; Sam Lattimore; Abdel Babiker; Kholoud Porter
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.